Last updated: September 3, 2026
Benoxinate hydrochloride and fluorescein sodium are established ophthalmic diagnostic agents used together to anesthetize the ocular surface and stain the cornea. The combination is marketed primarily for tonometry, foreign-body detection, corneal abrasion assessment, and contact-lens-related examinations. Its commercial profile is that of a mature, low-growth prescription ophthalmic product with limited patent protection, generic substitution risk, and meaningful supply-chain sensitivity.
The combination’s principal branded product, Fluress, has been associated with Akorn. Public sources do not disclose standalone revenue for Fluress or the broader benoxinate-fluorescein combination. Financial performance therefore must be assessed through prescription demand, product availability, generic competition, manufacturing continuity, and substitution by fluorescein strips or separate anesthetic products.
What is the market for benoxinate hydrochloride and fluorescein sodium?
The product combines two established ophthalmic ingredients:
| Ingredient |
Primary function |
Typical concentration in combination products |
| Benoxinate hydrochloride |
Topical ocular anesthetic |
0.4% |
| Fluorescein sodium |
Diagnostic corneal stain |
0.25% |
Benoxinate hydrochloride, also called oxybuprocaine, temporarily blocks corneal nerve conduction. Fluorescein sodium stains damaged epithelial tissue and assists with applanation tonometry and ocular-surface examination.
The commercial market includes:
- Combination ophthalmic solutions such as Fluress.
- Separate fluorescein sodium ophthalmic solutions.
- Fluorescein-impregnated paper strips.
- Separate topical anesthetic drops, including proparacaine and tetracaine.
- Preservative-free or unit-dose diagnostic products used in hospitals and ambulatory eye-care settings.
The combination is used mainly in ophthalmology, optometry, emergency departments, outpatient clinics, and diagnostic procedures. It is not a chronic-use medicine, so market volume depends on procedure counts rather than long-term patient adherence.
What FDA-approved products contain benoxinate hydrochloride and fluorescein sodium?
Fluress is the best-known U.S. combination product. Its labeling identifies fluorescein sodium and benoxinate hydrochloride ophthalmic solution as the active ingredients and describes use before ophthalmic procedures requiring topical anesthesia and fluorescein staining.[1]
| Product |
Active ingredients |
Dosage form |
U.S. commercial status |
| Fluress |
Fluorescein sodium 0.25%; benoxinate hydrochloride 0.4% |
Ophthalmic solution |
Historically marketed by Akorn; commercial continuity has been affected by Akorn’s financial distress |
| Generic or equivalent products |
Same active ingredients and concentrations may be available depending on supplier |
Ophthalmic solution |
Availability varies by manufacturer, distributor, and NDC status |
| Fluorescein-only products |
Fluorescein sodium |
Solution, strip, or other ophthalmic dosage forms |
Broad diagnostic substitution market |
| Benoxinate-only products |
Benoxinate hydrochloride |
Ophthalmic solution |
More limited U.S. market presence |
FDA labeling and DailyMed records should be distinguished from current commercial availability. A product can retain an approved label while having limited distribution, a discontinued NDC, or a temporary supply interruption.[1][2]
When does benoxinate-fluorescein lose exclusivity?
The combination has no meaningful remaining composition-of-matter exclusivity in the United States. Benoxinate hydrochloride and fluorescein sodium are long-established active ingredients, and the relevant product concepts date back several decades.
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Expired or not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material current protection identified |
| Combination-product exclusivity |
No current commercial barrier identified |
| Formulation exclusivity |
No publicly identified active barrier that would prevent equivalent products |
| Patent exclusivity |
No publicly identified active U.S. patent materially protecting the established combination |
The key commercial issue is therefore not loss of a future patent cliff. It is the continuing erosion of a mature product market through generic supply, alternative dosage forms, and institutional purchasing pressure.
What patents protect benoxinate hydrochloride and fluorescein sodium?
No active U.S. patent estate with material commercial significance has been publicly identified for the established benoxinate hydrochloride 0.4% and fluorescein sodium 0.25% ophthalmic combination.
The original composition, basic use, and conventional ophthalmic-solution concepts are old enough that any foundational patents would have expired. Current patent value would have to come from a later innovation, such as:
- A preservative-free formulation.
- A novel container or unit-dose delivery system.
- A stability-enhancing excipient system.
- A specialized combination with another diagnostic or therapeutic agent.
- A new manufacturing or packaging process.
- A differentiated formulation designed to reduce ocular irritation or contamination risk.
No such active patent portfolio is publicly associated with the conventional Fluress-type product in the primary FDA materials reviewed.[2][3]
Are there formulation patents for the combination?
The principal formulation risk is low from a patent perspective but high from a quality and manufacturing perspective. Ophthalmic solutions must meet sterility, particulate, stability, container-closure, and preservative requirements. Those requirements can create regulatory and operational barriers without creating long-term patent exclusivity.
A competitor may be able to obtain approval for an equivalent product while still facing:
- Sterile manufacturing capacity constraints.
- Limited access to suitable low-volume ophthalmic filling lines.
- Testing requirements for preservative concentration and stability.
- Packaging constraints for dropper bottles or unit-dose containers.
- Distributor qualification and hospital formulary requirements.
These barriers can support short-term pricing power during shortages, but they do not normally produce durable market exclusivity.
What is the Orange Book status of benoxinate hydrochloride and fluorescein sodium?
The Orange Book is relevant only to approved drug products for which FDA has identified patents or exclusivity information. The conventional benoxinate-fluorescein combination does not appear to have a current, commercially meaningful Orange Book patent listing that would delay an ANDA applicant through a patent-based statutory stay.[3]
| Orange Book issue |
Market implication |
| Listed patent protecting the combination |
No material active listing publicly identified |
| Paragraph IV exposure |
Limited, because there is no apparent active patent target |
| 30-month stay risk |
Not a central risk for the conventional product |
| ANDA approval barrier |
Primarily pharmaceutical equivalence, bioequivalence or product-specific requirements, labeling, and manufacturing |
| Pediatric or orphan exclusivity |
Not a material barrier |
An applicant seeking to market a generic ophthalmic solution would face FDA quality and approval requirements rather than a significant patent-based delay.
Which companies are challenging the product through generic competition?
The market is not defined by a single high-profile Paragraph IV challenger. Competition is more likely to arise from generic ophthalmic manufacturers, contract manufacturers, specialty ophthalmic suppliers, and alternative diagnostic products.
Potential competitive categories include:
- Generic manufacturers seeking approval for the same active ingredients and concentrations.
- Suppliers of fluorescein sodium strips.
- Manufacturers of separate proparacaine or tetracaine anesthetic products.
- Hospital and clinic suppliers offering procedure-specific diagnostic kits.
- International suppliers selling oxybuprocaine-fluorescein combinations outside the United States.
Publicly available sources do not establish a current, named Paragraph IV litigation campaign against Fluress. The absence of a significant patent challenge is consistent with the product’s old active ingredients and limited apparent patent protection.
What is the litigation status for benoxinate hydrochloride and fluorescein sodium?
No major active U.S. patent litigation involving the conventional benoxinate hydrochloride and fluorescein sodium combination has been identified in the principal public FDA materials and widely reported pharmaceutical litigation records reviewed for this analysis.
The more relevant legal issues are commercial and regulatory:
- Product discontinuation or supply interruption.
- Contract manufacturing disputes.
- Bankruptcy-related asset sales.
- Quality-system compliance.
- Product-liability claims involving improper use of topical anesthetics.
- Distribution of products without proper FDA authorization.
Topical ocular anesthetics carry specific safety risks. Repeated or unsupervised use can delay corneal healing and cause serious ocular injury. FDA labeling limits use to supervised diagnostic procedures and warns against patient self-administration.[1]
What FDA regulatory status applies to the combination?
The product is regulated as a prescription ophthalmic drug. FDA requirements include:
- Sterile manufacturing.
- Approved labeling.
- Appropriate active-ingredient strength and identity.
- Stability and preservative controls.
- Container-closure integrity.
- Compliance with current good manufacturing practice requirements.
FDA’s regulatory framework creates a higher entry threshold than the low cost of the active ingredients might suggest. Ophthalmic products must be manufactured as sterile products, and manufacturing failures can remove a supplier from the market even when demand remains stable.
The combination is not a biologic. Biosimilar competition is therefore irrelevant. The principal regulatory pathway for a competing product would be an abbreviated new drug application or another applicable generic-drug pathway, not a biosimilar application.
How has Akorn’s financial position affected the market?
Akorn’s bankruptcy and subsequent business disruption increased commercial risk for products historically associated with the company. Akorn filed for Chapter 11 protection in 2023 after financial and operational difficulties, including manufacturing and product-availability pressures.[4]
The effect on Fluress is more important operationally than strategically:
| Financial factor |
Effect on the product |
| Akorn distress |
Increased risk of supply interruption and reduced commercial support |
| Low active-ingredient cost |
Limits long-term pricing power |
| Sterile manufacturing |
Makes rapid replacement difficult |
| Small procedure-driven market |
Limits the incentive for large pharmaceutical companies to invest |
| Generic competition |
Pressures net pricing |
| Institutional purchasing |
Increases bid and formulary pressure |
| Alternative fluorescein formats |
Caps demand for the combination solution |
No public filing provides a reliable standalone revenue figure for Fluress. Akorn reported product-level information only selectively, and Fluress was not generally disclosed as a separate material revenue line in public financial reporting.[4]
What is the financial trajectory for benoxinate-fluorescein products?
The expected financial trajectory is mature and volume-sensitive rather than growth-oriented.
Historical phase
The product benefited from established use in ophthalmic examinations and a simple value proposition: one bottle supplied both anesthesia and fluorescein staining. Its strongest commercial advantages were convenience, workflow efficiency, and established clinician familiarity.
Current phase
The market is characterized by:
- Limited clinical differentiation.
- Low expected prescription growth.
- Generic and private-label pricing.
- Periodic shortages or supplier changes.
- Substitution by fluorescein strips and separate anesthetic drops.
- Dependence on ophthalmology and optometry procedure volumes.
Forward trajectory
Revenue is likely to remain flat to declining for a branded combination unless a supplier creates a differentiated product. Potential growth areas include:
- Preservative-free unit-dose delivery.
- Integrated diagnostic kits.
- Ambulatory and office-based eye-care expansion.
- Products designed to reduce contamination risk.
- Reliable supply contracts with hospitals and large optometry groups.
The combination is unlikely to support blockbuster economics. Its investment case depends on manufacturing reliability, low-cost sterile production, distribution reach, and the ability to avoid commodity pricing.
How strong is the patent estate for benoxinate hydrochloride and fluorescein sodium?
The patent estate is weak for the conventional combination.
| Patent-strength factor |
Assessment |
| Foundational active-ingredient patents |
Expired or commercially irrelevant |
| Composition protection |
Weak |
| Method-of-use protection |
Weak for routine staining and tonometry |
| Formulation protection |
No material active estate publicly identified |
| Device or packaging protection |
Could exist for later products but is not established for Fluress |
| Freedom-to-operate risk |
Generally lower than for patented ophthalmic therapies |
| Regulatory and manufacturing risk |
Higher than patent risk |
The principal defensibility comes from regulatory compliance, product reliability, customer relationships, and manufacturing capacity. Those assets can support a business but are not substitutes for enforceable patent protection.
What method-of-use patents cover the product?
Routine uses such as corneal staining, tonometry, foreign-body detection, and examination of ocular-surface damage are established diagnostic practices. No active method-of-use patent with material commercial effect has been publicly identified for the conventional combination.
A later patent could potentially claim a narrower use, dosing protocol, diagnostic workflow, or specialized patient population. Such protection would have limited value unless it covered a substantial share of the product’s actual demand and could be enforced against substitute products.
How does the combination compare with fluorescein strips and separate anesthetic drops?
| Attribute |
Benoxinate-fluorescein solution |
Fluorescein strips plus anesthetic |
Separate fluorescein solution plus anesthetic |
| Workflow |
One product |
Two products |
Two products |
| Sterility burden |
High |
Strip-specific |
High for liquid products |
| Dosing flexibility |
Moderate |
High procedural control |
High |
| Waste profile |
Bottle-use dependent |
Unit-dose format can reduce waste |
Varies |
| Contamination risk |
Depends on bottle design and handling |
Lower with single-use strips |
Depends on packaging |
| Patent differentiation |
Low |
Low to moderate by device design |
Low |
| Price sensitivity |
High |
High |
High |
| Institutional appeal |
Convenience-driven |
Infection-control and waste advantages |
Familiarity and flexibility |
Fluorescein strips are the most important commercial substitute where clinics prioritize single-use handling, storage convenience, and reduced bottle contamination risk. Separate anesthetic and fluorescein products may be preferred when clinicians want to adjust dosing or use different anesthetics.
What generic launch risks exist for the product?
A generic launch would face low patent risk but moderate execution risk.
Likely launch conditions
A new supplier would need to demonstrate:
- FDA-acceptable product quality.
- Sterility and stability.
- Consistent supply of both active ingredients.
- Commercial-scale ophthalmic filling capacity.
- Reliable packaging and labeling.
- Distributor access to ophthalmology and optometry accounts.
Market-entry scenarios
| Scenario |
Expected commercial effect |
| One additional reliable generic |
Moderate price erosion and greater purchasing leverage |
| Multiple generic entrants |
Commodity pricing and reduced branded share |
| Continued incumbent supply disruption |
Temporary price increases and customer switching |
| Strong adoption of fluorescein strips |
Structural decline in liquid-combination volume |
| Preservative-free differentiated entrant |
Potential premium segment |
| Hospital contracting by a reliable supplier |
Stable volume despite low unit pricing |
The largest risk for an incumbent is not a sudden patent-driven launch. It is gradual account migration after a shortage, followed by permanent substitution.
What geographic markets offer the greatest opportunity?
The U.S. market has the clearest regulatory structure but also the strongest generic and institutional pricing pressure. International opportunities vary because oxybuprocaine, fluorescein, and combination ophthalmic products have different approval histories and prescribing patterns.
| Geography |
Commercial characteristics |
| United States |
Mature demand, FDA sterile-product requirements, generic substitution, strong distributor influence |
| European markets |
Oxybuprocaine is more familiar in some countries; national reimbursement and procurement rules vary |
| Canada |
Smaller market with centralized purchasing and limited product breadth |
| Latin America |
Potential demand growth, but regulatory and distributor risks are higher |
| Asia-Pacific |
Large ophthalmology populations, variable regulatory pathways, strong local-manufacturer competition |
International expansion would require country-specific registrations, local pharmacovigilance, labeling compliance, and supply arrangements. The active ingredients themselves do not create a durable international moat.
What licensing deals affect benoxinate-fluorescein products?
No major public licensing transaction specifically covering benoxinate hydrochloride and fluorescein sodium has been identified. The established product is more likely to move through:
- Contract manufacturing agreements.
- Asset purchases.
- Distributor arrangements.
- Private-label supply contracts.
- Hospital or group-practice purchasing agreements.
The most valuable commercial agreement would likely be a reliable sterile-manufacturing and distribution arrangement rather than a patent license. Because the conventional formulation has limited patent protection, licensing economics are constrained.
What revenue exposure does the product create for manufacturers?
Standalone revenue exposure is difficult to quantify because manufacturers generally report ophthalmic portfolios in aggregate rather than disclose this product separately. The product’s financial contribution is likely modest relative to high-value chronic ophthalmic therapies, injectable drugs, or branded surgical products.
Its value to a supplier can still be meaningful when it:
- Uses underutilized sterile filling capacity.
- Complements a broader ophthalmic portfolio.
- Supports a hospital or optometry account.
- Generates recurring procedure-based demand.
- Provides cross-selling opportunities with fluorescein strips or other diagnostic products.
The product is more attractive as part of a portfolio than as a standalone branded asset.
Key Takeaways
- Benoxinate hydrochloride and fluorescein sodium are mature ophthalmic diagnostic ingredients used for topical anesthesia and corneal staining.
- Fluress is the principal historically recognized U.S. combination product associated with the market.
- No material active U.S. patent estate has been publicly identified for the conventional 0.4% benoxinate and 0.25% fluorescein combination.
- Paragraph IV litigation and Orange Book patent barriers do not appear to be central commercial risks.
- Biosimilar competition is irrelevant because the product is a conventional small-molecule ophthalmic drug.
- The main risks are sterile manufacturing, supply continuity, generic pricing, distributor access, and substitution by fluorescein strips.
- Akorn’s financial distress increased supply and continuity risk for products associated with the company.
- No reliable standalone revenue figure is publicly disclosed for Fluress or the broader combination.
- Long-term commercial value depends on manufacturing reliability, differentiated packaging, preservative-free delivery, and institutional distribution.
- The product is more likely to produce stable niche revenue than significant growth or blockbuster returns.
FAQs About Benoxinate Hydrochloride and Fluorescein Sodium
Is benoxinate hydrochloride the same as proparacaine?
No. Both are topical ocular anesthetics, but they are different active ingredients. Benoxinate hydrochloride is also known as oxybuprocaine, while proparacaine is a separate anesthetic used in ophthalmic examinations.
Can fluorescein sodium be sold without benoxinate hydrochloride?
Yes. Fluorescein sodium is marketed separately in ophthalmic solutions and impregnated strips. Separate fluorescein products are important substitutes for the combination product.
Is Fluress still commercially available in the United States?
Availability has varied because of the financial and operational disruption affecting Akorn and the broader sterile ophthalmic supply chain. FDA labeling records should not be treated as proof of uninterrupted commercial distribution.[1][4]
Does the product have a 30-month Paragraph IV litigation risk?
No material current risk has been publicly identified for the conventional combination because no significant active Orange Book patent estate has been identified for the product.[3]
Could a preservative-free version obtain premium pricing?
It could command a premium if it demonstrates meaningful advantages in contamination control, tolerability, unit-dose handling, or institutional workflow. The premium would depend on FDA approval, reliable supply, and evidence that customers will pay more than commodity prices.
References
-
DailyMed. (n.d.). Fluress: Fluorescein sodium and benoxinate hydrochloride ophthalmic solution prescribing information. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Akorn Operating Company LLC. (2023). Voluntary petition and related bankruptcy filings. United States Bankruptcy Court.
